Document is current
Any future updates will be listed below
-
Authors
Carrico, Justin
Zhao, Yang
Jia, Xiaoying
Brodtkorb, Thor-Henrik
Mendelsohn, Alan
Lowry, Simon
- License Information
-
More Information
Article History
First Online: 26 March 2020
Compliance with Ethical Standards
:
: Sun Pharmaceutical Industries, Inc. provided funding for all research contributing to this manuscript, and was also involved in the design and conduct of the study; collection, management, and analysis of the data; and preparation, review, and approval of the manuscript.
: YZ, AM, and SL were employees of Sun Pharmaceutical Industries, Inc. at the time of this analysis. XJ, JC, and THB are employees of RTI-Health Solutions, all of whom were contracted by Sun Pharmaceutical Industries, Inc. to support the study.
: Carrico J, Zhao Y, Jia X, Brodtkorb TH, Mendelsohn A, Lowry S. Budget Impact of Introducing Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in the United States. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus; 22–25 October 2018; Orlando, FL.
